Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the CHEST Score: The West Birmingham Atrial Fibrillation Project.
Daniele Pastori,Kazuo Miyazawa,Farhan Shahid,Yan-Guang Li,Gregory Y H Lip
DOI: https://doi.org/10.1161/jaha.120.017519
IF: 6.106
2021-03-06
Journal of the American Heart Association
Abstract:Background Sustained atrial high‐rate episodes (SAHREs) among individuals with a cardiac implantable electronic device are associated with an increased risk of adverse outcomes. Risk stratification for the development of SAHREs has never been investigated. We aimed to assess the performance of the C 2 HEST (coronary artery disease or chronic obstructive pulmonary disease [1 point each], hypertension [1 point], elderly [age ≥75 years, 2 points], systolic heart failure [2 points], thyroid disease [1 point]) score in predicting SAHREs in patients with cardiac implantable electronic devices without atrial fibrillation. Methods and Results Five Hundred consecutive patients with cardiac implantable electronic devices in the West Birmingham Atrial Fibrillation Project in the United Kingdom were followed since the procedure to observe the development of SAHREs, defined by atrial high‐rate episodes lasting >24 hours. Risk factors and incidence of SAHREs were analyzed. The predictive value of the C 2 HEST score for SAHRE prediction was evaluated. Over a mean follow‐up of 53.1 months, 44 (8.8%) patients developed SAHREs. SAHREs were associated with higher all‐cause mortality ( P <0.001) and ischemic stroke ( P =0.001). Age and heart failure were associated with SAHRE occurrence. The incidence of SAHREs increased by the C 2 HEST score (39% higher risk per point increase). Among patients with a C 2 HEST score ≥4, the incidence of SAHREs was 3.62% per year (95% CI, 2.14–5.16). The C 2 HEST score had moderate predictive capability (area under the curve, 0.73; 95% CI, 0.64–0.81) and discriminative ability (log‐rank P =0.003), which was better than other clinical scores (CHA 2 DS 2 ‐VASc, CHADS 2 , HATCH). Conclusions The C 2 HEST score predicted SAHRE incidence in patients without atrial fibrillation who had an cardiac implantable electronic device, with the highest risk seen in patients with a C 2 HEST score ≥4 The benefit of using the C 2 HEST score in clinical practice in this patient population needs further investigation. Nonstandard Abbreviations and Acronyms AHRE atrial high‐rate episode C 2 HEST coronary artery disease or chronic obstructive pulmonary disease (1 point each), hypertension (1 point), elderly (age ≥75 years, 2 points), systolic heart failure (2 points), thyroid disease (1 point) CHADS 2 congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack CHA 2 DS 2 ‐VASc congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category HATCH hypertension, age ≥75 years, transient ischemic attack or stroke, chronic obstructive pulmonary disease, and heart failure OAC oral anticoagulation SAHRE sustained atrial high‐rate episode Clinical Perspective What Is New? Sustained atrial high‐rate episodes in patients with cardiac implantable electronic device are common, with age and heart failure being independent risk factors. The risk of sustained atrial high‐rate episodes can be stratified by the C 2 HEST (coronary artery disease or chronic obstructive pulmonary disease [1 point each], hypertension [1 point], elderly [age ≥75 years, 2 points], systolic heart failure [2 points], thyroid disease [1 point]) score with moderate predictive accuracy. What Are the Clinical Implications? For high‐risk patients (C 2 HEST score ≥4), a more intensive (eg, shorter follow‐up interval) or continuous (eg, remote monitoring) device interview may be needed, enabling early detection and early treatment of subclinical atrial fibrillation. Atrial high‐rate episodes (AHREs) are common among patients with cardiac implantable electronic devices (CIEDs), with a prevalence ranging from 30%<a class="tab-link" href="#jah -Abstract Truncated-
cardiac & cardiovascular systems